UK biotechnology company TRIMTECH Therapeutics announced on Monday that it has entered into a strategic research collaboration, option and licence agreement with Biogen International GmbH, part of US biotechnology company Biogen Inc (NASDAQ:BIIB), to develop small molecule protein degraders targeting neurodegenerative diseases.
The collaboration will leverage TRIMTECH's proprietary TRIM21-based targeted protein degradation technology to discover and develop therapies targeting toxic protein aggregates associated with neurodegenerative conditions.
Under the agreement, TRIMTECH is eligible to receive up to USD32m in upfront and research milestone payments, with total potential payments of up to USD411m, plus royalties. If Biogen exercises its option, it will receive a global exclusive licence to the resulting degraders and assume responsibility for further development and commercialisation.
TRIMTECH's technology uses small molecule TRIMTAC and TRIMGLUE degraders designed to access the central nervous system and selectively break down toxic protein aggregates and oligomers implicated in neurodegenerative diseases.
Insilico Medicine and CMS to collaborate further on CNS diseases
Accord BioPharma's second pegfilgrastim biosimilar to NEULASTA approved by US FDA
Nona Biosciences and Lonza collaborate on antibody-based BBB-crossing technology for CNS diseases
Silo Pharma regains compliance with Nasdaq minimum bid price
Lilly acquires 4E Therapeutics to advance non-opioid chronic pain treatment
Bayer receives FDA approval for AMBELVIST MRI contrast agent
Lynk Pharmaceuticals' partner Formation Bio doses first participant in BLKR201 Phase 1 trial
Verge Labs and Tenacia Biotechnology collaborate on advancing Tenacia's CNS pipeline
Lunai Bioworks completes USD20m preferred issuance to acquire CNS delivery and neurotherapeutic IP
Solvonis Therapeutics appoints Water Tower Research to strengthen US market positioning
Solvonis Therapeutics secures second US patent for PTSD compound series
Insilico Medicine and Tenacia expand AI-driven R&D collaboration
TheraCryf advances lead addiction programme to final preclinical stage
Collegium to acquire AZSTARYS from Corium Therapeutics
Sanofi's venglustat receives FDA Breakthrough Therapy designation for type 3 Gaucher disease